Osteoporosis-Clinical Trials

OR22-1

Effect of Denosumab Treatment in Postmenopausal Women with Osteoporosis: Eight-Year Results from the Freedom Extension, Phase 3 Clinical Trial
E Michael Lewiecki, Socrates Papapoulos, Kurt Lippuner, Christian Roux, Celia JF Lin, David L Kendler, Maria L Brandi, Edward Czerwinski, Edward Franek, Peter Lakatos, Salvatore Minisola, Jean-Yves Reginster, Soren Jensen, Nadia Daizadeh, Andrea Wang, Mary Gavin, Rachel B Wagman and Henry G Bone

OR22-2

Denosumab for the Treatment of Men with Low Bone Mineral Density: 24-Month Results from the Adamo Trial
Bente L Langdahl, Christence S Teglbjaerg, Pei-Ran Ho, Roland Chapurlat, Edward Czerwinski, David L Kendler, Jean-Yves Reginster, Alan Kivitz, E Lewiecki, Paul D Miller, Michael A Bolognese, Michael R McClung, Henry G. Bone III, Östen Ljunggren, Bo Abrahamsen, Ugis Gruntmanis, Yu-Ching Yang, Rachel B Wagman, Suresh Siddhanti and Eric Orwoll

OR22-3

The PTHrP1-34 Analog, Abaloparatide (BA058), Induces Consistent, Marked and Rapid Increases in Hip and Spine BMD with Compared to Placebo and Teriparatide
John Yates, Paul D Miller, Michael A Bolognese, Grattan Woodson, Ivo Valter, Marcie Clarkin, Gary Hattersley, Morten Karsdal and Claus Christiansen

OR22-4

A Transdermal Patch Delivering the PTHrP1-34 Analog, Abaloparatide (BA058), Dose-Dependently Increases Spine and Hip BMD Compared to Placebo
John Yates, Paul D Miller, Michael Anthony Bolognese, Grattan Woodson, Ivo Valter, Marcie Clarkin, Gary Hattersley, Kris Hansen, Morten Karsdal and Claus Christiansen

OR22-5

Pioglitazone Increases Femoral Neck Bone Marrow Fat Content and Proportionately Reduces Total Hip Bone Mineral Density
Naim M Maalouf, Ildiko Lingvay, Beverley Huet, Madhuri Poduri, Qing Yuan, Lidia Szczepaniak, Xilong Li and Edward Szczepaniak